Search
Avibactam
go.drugbank.com/drugs/DB09060ApprovedInvestigationalAs there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 years old who have limited or not alternative treatment options. … This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract
Mixtures: ZAVİCEFTA 2 G/0.5 G İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 10 ADETProducts: ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 2G/0.5GMethadyl acetate
go.drugbank.com/drugs/DB01433ExperimentalIllicitA narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.
Olodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalActivation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). … Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production.
Mixtures: SPIOLTO RESPIMAT 2.5 MCG/2.5 MCG INHALASYON ÇÖZELTISI,1 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesN-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
go.drugbank.com/drugs/DB13948ExperimentalIt has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen. … 25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist.
Categories: Serotonin 5-HT2 Receptor AgonistsMerimepodib
go.drugbank.com/drugs/DB04862InvestigationalMerimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.
Susoctocog alfa
go.drugbank.com/drugs/DB11606ApprovedInvestigationalSusoctocog alfa is a glycoprotein containing a 90 kDa heavy chain and a 80 kDa light chain with the naturally-occuring B domain replaced with a twenty-four amino acid linker. … Susoctocog alfa was approved by the FDA in October 2014 and is marketed under the brand name Obizur for intravenous injection.
UCB-1184197
go.drugbank.com/drugs/DB05092Investigationalantagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple Sclerosis (MS … CDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis.
Frespaciguat
go.drugbank.com/drugs/DB21683InvestigationalFrespaciguat is under investigation in clinical trial NCT05612035 (Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With … Frespaciguat has a monoisotopic molecular weight of 608.14 Da.
Eravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalIt was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections [A38727].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesAnisindione
go.drugbank.com/drugs/DB01125Approvedwell as the anticoagulant proteins C and S, in the liver. … is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as